Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Influence of Omeprazole on Multidrug Resistance Protein 3 Expression in Human Liver

Monika Hitzl, Kathrin Klein, Ulrich M. Zanger, Peter Fritz, Andreas K. Nüssler, Peter Neuhaus and Martin F. Fromm
Journal of Pharmacology and Experimental Therapeutics February 2003, 304 (2) 524-530; DOI: https://doi.org/10.1124/jpet.102.043547
Monika Hitzl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathrin Klein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich M. Zanger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Fritz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas K. Nüssler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Neuhaus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin F. Fromm
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Multidrug resistance protein (MRP) 3 transports bile salts and conjugated xenobiotics from cells (hepatocytes and enterocytes) into the blood. Hepatic MRP3 expression is low under normal conditions but is markedly up-regulated during cholestasis. Since little is known about additional factors increasing human hepatic MRP3 expression, we investigated the variability of MRP3 expression in a large collection of human livers and factors contributing to variable MRP3 expression in liver and HepG2 cells. MRP3 was measured in 62 human livers from patients with and without omeprazole treatment and in HepG2 cells with and without omeprazole or β-naphthoflavone treatment. Livers of patients treated with omeprazole showed 4.8-fold (P< 0.0001) higher MRP3 protein expression compared with the remainder of the population. Accordingly, MRP3 mRNA and protein were induced 2.4- and 1.8-fold, respectively (P < 0.01 andP < 0.05), in HepG2 cells treated with omeprazole. Finally, MRP3 was induced in HepG2 cells by β-naphthoflavone. In summary, treatment with omeprazole and β-naphthoflavone is a determinant of variable human hepatic MRP3 expression.

Footnotes

  • Supported by the Deutsche Forschungsgemeinschaft (Bonn, FR 1298/2-1), Grant 01 GG 9846 from the German Federal Ministry of Education and Science, and the Robert Bosch Foundation (Stuttgart, Germany).

  • DOI: 10.1124/jpet.102.043547

  • Abbreviations:
    HIV
    human immunodeficiency virus
    MRP
    multidrug resistance protein
    PCR
    polymerase chain reaction
    TBS
    Tris-buffered saline
    TBS-T
    Tris-buffered saline/Tween 20
    DMSO
    dimethyl sulfoxide
    RT-PCR
    reverse transcription polymerase chain reaction
    a.u.
    arbitrary units
    • Received August 27, 2002.
    • Accepted October 3, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 304 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 304, Issue 2
1 Feb 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Influence of Omeprazole on Multidrug Resistance Protein 3 Expression in Human Liver
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Influence of Omeprazole on Multidrug Resistance Protein 3 Expression in Human Liver

Monika Hitzl, Kathrin Klein, Ulrich M. Zanger, Peter Fritz, Andreas K. Nüssler, Peter Neuhaus and Martin F. Fromm
Journal of Pharmacology and Experimental Therapeutics February 1, 2003, 304 (2) 524-530; DOI: https://doi.org/10.1124/jpet.102.043547

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Influence of Omeprazole on Multidrug Resistance Protein 3 Expression in Human Liver

Monika Hitzl, Kathrin Klein, Ulrich M. Zanger, Peter Fritz, Andreas K. Nüssler, Peter Neuhaus and Martin F. Fromm
Journal of Pharmacology and Experimental Therapeutics February 1, 2003, 304 (2) 524-530; DOI: https://doi.org/10.1124/jpet.102.043547
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Ligustrazine Attenuates Liver Fibrosis
  • MK-5046, BRS-3 allosteric agonist
  • Renal Pharmacology of 8-Aminopurines
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics